By Christy Santhosh June 12 (Reuters) - Jazz Pharmaceuticals said on Friday its lung cancer drug Zepzelca failed to meet the ...

The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy.

GSK is making its largest acquisition in more than a decade, and Montgomery County has a clear stake in what comes next, ...

Scammers used the identity of Brian Druker, MD, the renowned leukemia researcher known for his work developing imatinib ...

Although cancer treatments are improving fast, prevention has so far been mostly about promoting a healthy lifestyle. But ...

The technology is being rolled out at the Royal Surrey NHS Foundation Trust.

Lung cancer may not be the most common cancer diagnosis in the United States—that would be prostate cancer for men and breast ...

Following another phase 3 failure for Gilead Sciences’ Trodelvy, the race to bring a TROP2 antibody-drug conjugate (ADC) to patients with first-line non-small cell lung cancer (NSCLC) has narrowed. | ...

Scientists have identified proteins that could signal increased lung cancer risk, as well as a drug that could reduce the ...

A new research project in Minnesota aims to increase lung cancer screenings in rural areas. Rural residents have higher ...

An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small ...

When Garen was diagnosed with lung cancer, biomarker testing helped focus his treatment options, inform his treatment ...